Compare Novo Nordisk A/S (NVO) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Zeta Global Holdings Corp — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Zeta Global Holdings Corp trades at $33.09 (market cap $8.29B). The key difference: Novo Nordisk A/S is far larger — about 19.9× Zeta Global Holdings Corp's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Zeta Global Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Zeta Global Holdings Corp for 19 Days on average.
| NVO | ZETA | |
|---|---|---|
Market Cap | $165.31B | $8.29B |
Volume | 11,432,838 | 7,156,795 |
Sector | Health | Technology |
52-Week High | $63.98 | $33.74 |
52-Week Low | $35.29 | $14.55 |
Typical Hold Time | 116 Days | 19 Days |
Enterprise Value | $179.56B | $8.18B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
ZETA trades at $33.09, down 1.93% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and support at $32. Fundamentally, revenue grew to $1.3B in 2025 with a gross margin of 59.48%, but net income remains negative. Recent quarters saw EPS beats, and the company is expanding internationally with a new UK hub. Analyst sentiment is positive with 12 buy ratings and a $32.40 consensus target.
The outlook is cautiously optimistic due to strong revenue growth and AI-driven customer adoption, but profitability risks persist with negative net margins and high valuation multiples. Investors should weigh growth potential against execution risks and competitive pressures in the tech services sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
